Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 18Carcinoma, Transitional Cell 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Ureteral Neoplasms 1Transitional Cell Bladder Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Cancer 1Infiltrating Bladder Urothelial Carcinoma 1

Interventions

pembrolizumab 5enfortumab vedotin 3Gemcitabine 3dodecyl maltoside 2Sunitinib 2Cisplatin 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tucatinib 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1palbociclib 1niraparib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1cabozantinib 1Valproic Acid 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Sirolimus 1Rivaroxaban 1Ringer's acetate 1Radiosurgery 1Radiation Dose Hypofractionation 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Cystectomy × 1 year × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡